

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) An antibody which
  - (i) binds with an epitope on human dendritic cells (DCs) wherein said DCs comprise a DC population of a maturational stage between immature and mature DCs displaying one or more surface markers of both immature and mature human DCs from peripheral blood mononuclear cells (PBMCs), but
  - (ii) does not react bind with other PBMCs.
2. (Canceled) The antibody of claim 1, wherein said DCs comprise a DC population of a maturational stage between immature and mature DCs.
3. (Previously Presented) The antibody of claim 1, wherein said DCs are HLA-DR<sup>+</sup>.
4. (Previously Presented) The antibody of claim 1, wherein said DCs are selected from the group consisting of CD64<sup>-</sup>, CD33<sup>+</sup>, CD45RA<sup>+</sup>, CD11c<sup>+</sup> and p55<sup>-</sup> and CD16<sup>+</sup>.
5. (Currently Amended) The antibody of claim 1, wherein said DCs are of restricted size and granularity located between lymphocytes and monocytes as measured by light microscopy or light scatter display.
6. (Currently Amended) The antibody of claim 1, wherein said antibody is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a humanized antibody, a bispecific antibody, a synthetic antibody, an antibody fragment capable of binding to said epitope, and a chemically modified derivative thereof capable of binding to said epitope .
7. (Canceled)

8. (Previously Presented) The antibody of claim 6, wherein said DCs bind to the antibody produced by hybridoma cell line DSM ACC2241, by hybridoma cell line DSM ACC 2399 or by hybridoma cell line DSM ACC 2398.

9. (Previously Presented) The antibody of claim 6, which is produced by hybridoma cell line DSM ACC2241, DSM ACC 2399 or DSM ACC 2398.

10. (Previously Presented) A stable antibody-producing cell line which is capable of producing an antibody of claim 1.

11. (Previously Presented) The cell line of claim 10, wherein said cell line is a hybridoma cell line having the deposit number DSM ACC2241, DSM ACC 2398 or DSM ACC 2399.

12-15 (Canceled)

16. (Previously Presented) A method for preparing an antibody capable of binding to human dendritic cells (DCs) from peripheral blood mononuclear cells (PBMCs) or a fragment or derivative thereof capable of binding to said epitope on the DCs or at least one immunoglobulin chain thereof, comprising:

- (a) culturing the cell line of claim 10; and
- (b) isolating said antibody, functional fragment or derivative thereof or at least one immunoglobulin chain thereof from the culture.

17. (Currently Amended) An antibody, an epitope-binding fragment thereof or derivative thereof or immunoglobulin chain encoded by a polynucleotide encoding at least a variable region of an immunoglobulin chain of said antibody which binds with an epitope on human dendritic cells (DCs) wherein said DCs comprise a DC population of a maturational stage between immature and mature DCs displaying one or more surface markers of both ~~immature or mature human DCs from peripheral blood mononuclear cells (PBMCs)~~, but does not ~~react~~ bind with other PBMCs or obtainable by the method of claim 16.

18-29 (Canceled)

30. (Previously Presented) A method for isolating or identifying DCs from peripheral blood, comprising:

- (a) contacting a sample of peripheral blood with the antibody of claim 1;
- (b) detecting the presence of antibody/DC complexes; and optionally
- (c) recovering DCs which have bound to said antibody or functional fragment thereof.

31 – 40 (Canceled)

41. (Previously Presented) A kit comprising the antibody of claim 1, and optionally comprising additional components.

42. (Previously Presented) A composition comprising the antibody of claim 1.

43. (Original) The composition of claim 42 which is a pharmaceutical composition optionally further comprising a pharmaceutical acceptable carrier.

44. (Canceled)

45. (Previously Presented) A diagnostic composition comprising the antibody of claim 1, and optionally suitable means for detection.

46-57. (Canceled)

58. (Previously Presented) The antibody of claim 1, wherein the antibody binds with an epitope on P-selectin glycoprotein ligand-1 (PSGL-1).

59. (Previously Presented) The antibody of claim 58, wherein said epitope is a carbohydrate moiety of PSGL-1.

60. (Previously Presented) The antibody of claim 1, wherein the antibody binds to the same epitope on human dendritic cells (DCs) to which the antibody produced by hybridoma cell line DSM ACC2241 binds.

61. (Previously Presented) The antibody of claim 60, where the antibody produced by hybridoma cell line DSM ACC2241 is M-DC8.

62. (Previously Presented) The antibody of claim 1, wherein the antibody comprises the heavy chain variable region of SEQ ID NO:2 and the light chain variable of SEQ ID NO:4.

63. (Previously Presented) An epitope binding fragment of the antibody of claim 62.